Influence of dose rate on therapeutic success of radioiodine therapy of functional thyroid autonomy.

OBJECTIVE: To evaluate the effect of dose rate on the therapeutic success of radioiodine therapy (RIT) by retrospective analysis of two groups of patients with different dose rates during RIT. METHODS: The average dose rate until deposition of 50% of the total radiation dose achieved (the DL50 value) was calculated. Ninety patients with autonomy of the thyroid receiving radiation doses between 300 and 400 Gy were separated in groups with high DL50 values (the DL50 H group) and low DL50 values (the DL50L group). Before and 4 months after RIT free triiodothyronine (FT3), free thyroxine (FT4), basal thyroid stimulating hormone (TSHB), stimulated TSH (TSHS), thyroidal technetium uptake (TcTU), and the existence of focal abnormalities in thyroid scintigraphy were evaluated. RESULTS: The DL50 H and DL50L groups showed no differences before RIT in the parameters assessed as well as in total achieved dose and autonomous thyroid volume. After therapy a significant difference was found in TSHB with higher values in DL50 H (1.89+/-1.49 vs. 1.31+/-1.48 mU . l, P<0.05), FT4 showed a trend to lower values (13.8+/-4.0 vs. 16.1+/-6.2 pmol . l, P=0.09). CONCLUSION: The DL50 value has an influence on therapeutic success of RIT. This influence is only discrete and not likely to produce clinically relevant effects in the practical use of RIT.

99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy.

Familial amyloidotic polyneuropathy (FAP) caused by amyloidogenic transthyretin (ATTR) mutations is the most common form of hereditary amyloidosis. We investigated the diagnostic value of the bone scanning agent technetium-99m 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) in this disease. Eight patients (four males, four females; age 54.4+/-8.3 years, range 43-67 years) with ATTR-FAP proven by immunohistochemistry and molecular analysis and a control group comprising ten oncological out-patients (five males, five females; age 53.4+/-8.5 years, range 34-66 years) without evidence of bony metastases were studied using 99mTc-DPD. Whole body tracer retention was 80.1%+/-10.3% (range 65.1%-94.8%) in FAP patients and 55.7%+/-8.1% (range 40.2%-66.7%) in controls at 3 h p.i. (P<0.001), and cardiac uptake was 7.3%+/-2.2% (range 4.2%-10.1%) in FAP patients and 3.1%+/-0.5% (range 2.3%-4.0%) in controls (P<0.001). The heart/whole body uptake ratio was 8.9%+/-1.7% (range 6.5%-11.0%) in FAP patients and 5.6%+/-0.5% (range 5.1%-6.8%) in controls (P<0.001). The three FAP patients with the highest cardiac tracer uptake had cardiomyopathy or arrhythmia. 99mTc-DPD scintigraphy is proposed as a simple and valuable diagnostic aid to evaluate the severity of the disease and the risk of concomitant heart problems.